Rapt Therapeutics (RAPT)
(Delayed Data from NSDQ)
$3.98 USD
-0.03 (-0.75%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $3.98 0.00 (0.00%) 6:46 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Rapt Therapeutics [RAPT]
Reports for Purchase
Showing records 1 - 20 ( 74 total )
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Our Thoughts on Tivumecirnon + Keytruda Data in HNSCC; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Awaiting Zelnecirnon Regulatory Clarity; 2023 Financials; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
FDA Clinical Hold Creates Zelnecirnon Uncertainty; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
FDA Clinical Hold Creates Zelnecirnon Uncertainty; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Major RPT193 Phase 2b Atopic Dermatitis Catalyst in Mid-2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Positive FLX475 + Keytruda Combo Data at SITC; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
All Eyes on RPT193 Atopic Dermatitis Program; 2Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
FLX475 Biomarker Data Supports Efficacy Profile; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Further FLX475 Data Approaches in 2H23; 1Q23 Financials; Lowering PT to $41
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
RPT193 Phase 2a Asthma Study Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Competitor Atopic Dermatitis Data Does Not Change Thesis; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
RPT193 Phase 2 Data Pushed to Mid-2024; 2022 Financials; Modulating PT to $43; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Encouraging Activity for FLX475 at ESMO IO; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
FLX475 Data Slated For ESMO-IO; 3Q22 Financials; Modulating PT to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
RPT193 Mid-Stage Programs; 2Q22 Financial Results; Raising PT to $53
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
RPT193 Phase 2 Trial Initiation; 1Q22 Financial Results; Reiterate Buy; PT Down to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Healthcare Coverage Update - Dropping Coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
1Q2022 Update - Clinical Plans Remain on Track with Cash to Execute - Buy
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z